Vasoactive intestinal peptide enhancement of antigen-induced differentiation of a cultured line of mouse thymocytes

^a Departments of Medicine and Microbiology, University of California, San Francisco, California 94143–0711, USA
^b Howard Hughes Medical Institute, University of California, San Francisco, California 94143–0711, USA
^c The Scripps Research Institute, La Jolla, California 92037, USA

The prominence of vasoactive intestinal peptide (VIP) in rodent thymic neurons suggested that this potent mediator of T cell functions may alter developmental responses of thymocytes to T cell receptor (TCR) -dependent stimulation. CD4⁺8⁺ DPK cells derived from a thymic lymphoma of a TCR transgenic mouse respond to pigeon cytochrome C (PCC) antigen in association with distinct I-E MHC II haplotypes on antigen-presenting cells (APCs) by differentiating into CD4⁺8^- T cells. The specific recognition of VIP by two types of homologous G-protein-coupled receptors (VIPR1 and VIPR2) on DPK cells was attributable predominantly to VIPR1 before and to VIPR2 after exposure to APCs and PCC, as assessed by quantification of the respective mRNAs. PCC-evoked differentiation of DPK cells was enhanced significantly by 1 to 100 nM VIP after 3 to 4 days. The effects of VIP analogs with VIPR type selectivity implied that VIP enhancement of differentiation of DPK cells was mediated principally by VIPR2. Differential reduction in the expression of each type of VIPR by transfection of DPK cells with plasmids encoding the respective antisense mRNAs confirmed the central role of VIPR2 in VIP-enhanced conversion to CD4⁺8^- T cells. The suppression of DPK cell differentiation by inhibitors of adenylyl cyclase and protein kinase A suggested a transductional role for VIP-elicited increases in [cAMP]_i. That the changes in frequency of CD4⁺8⁺ and CD4⁺8^- DPK cells reflected principally differentiation was supported by the lack of consistent differences between the two subsets in the effects of VIP and VIPR2 agonist on cell number, viability, apoptosis, and proliferation. VIP may be one endogenous mediator that explains the unique thymic microenvironment for topographically specific development of T cells.—Pankhaniya, R., Jabrane-Ferrat, N., Gaufo, G. O., Sreedharan, S. P., Dazin, P., Kaye, J., Goetzl, E. J. Vasoactive intestinal peptide enhancement of antigen-induced differentiation of a cultured line of mouse thymocytes. FASEB J. 12, 119–127 (1998)

Key Words: neuropeptide • immunology • T lymphocyte • receptor • apoptosis

This article has been cited by other articles:

				M. Delgado, D. Pozo, and D. Ganea The Significance of Vasoactive Intestinal Peptide in Immunomodulation Pharmacol. Rev., June 1, 2004; 56(2): 249 - 290. [Abstract] [Full Text] [PDF]

				J. K. Voice, C. Grinninger, Y. Kong, Y. Bangale, S. Paul, and E. J. Goetzl Roles of Vasoactive Intestinal Peptide (VIP) in the Expression of Different Immune Phenotypes by Wild-Type Mice and T Cell-Targeted Type II VIP Receptor Transgenic Mice J. Immunol., January 1, 2003; 170(1): 308 - 314. [Abstract] [Full Text] [PDF]

				D. Ganea and M. Delgado VASOACTIVE INTESTINAL PEPTIDE (VIP) AND PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AS MODULATORS OF BOTH INNATE AND ADAPTIVE IMMUNITY Crit. Rev. Oral. Biol. Med., May 1, 2002; 13(3): 229 - 237. [Abstract] [Full Text]

				J. K. VOICE, G. DORSAM, H. LEE, Y. KONG, and E. J. GOETZL Allergic diathesis in transgenic mice with constitutive T cell expression of inducible vasoactive intestinal peptide receptor FASEB J, November 1, 2001; 15(13): 2489 - 2496. [Abstract] [Full Text] [PDF]

				E. J. Goetzl, J. K. Voice, S. Shen, G. Dorsam, Y. Kong, K. M. West, C. F. Morrison, and A. J. Harmar Enhanced delayed-type hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC2 receptor for vasoactive intestinal peptide PNAS, October 31, 2001; (2001) 241503798. [Abstract] [Full Text] [PDF]

				G. DORSAM, J. VOICE, Y. KONG, and E. J. GOETZL Vasoactive Intestinal Peptide Mediation of Development and Functions of T Lymphocytes Ann. N.Y. Acad. Sci., December 1, 2000; 921(1): 79 - 91. [Abstract] [Full Text] [PDF]

				W. Savino and M. Dardenne Neuroendocrine Control of Thymus Physiology Endocr. Rev., August 1, 2000; 21(4): 412 - 443. [Abstract] [Full Text] [PDF]

				N. JABRANE-FERRAT, D. BLOOM, A. WU, L. LI, D. LO, S. P. SREEDHARAN, C. W. TURCK, and A. E. J. GOETZL Enhancement by vasoactive intestinal peptide of {gamma}-interferon production by antigen-stimulated type 1 helper T cells FASEB J, February 1, 1999; 13(2): 347 - 353. [Abstract] [Full Text]

				E. J. Goetzl, J. K. Voice, S. Shen, G. Dorsam, Y. Kong, K. M. West, C. F. Morrison, and A. J. Harmar Enhanced delayed-type hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC2 receptor for vasoactive intestinal peptide PNAS, November 20, 2001; 98(24): 13854 - 13859. [Abstract] [Full Text] [PDF]